Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

NRX Nurexone Biologic Inc

0,66

-0,02 (-2,94%)

28 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

New Collaboration Could Revolutionize Treatment of Chronic Spinal Cord Injuries

In January 2023,

To read the full story on AllPennyStocks.com, click here.

Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Nurexone Biologic Charts.

Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Nurexone Biologic Charts.

News Nurexone Biologic Inc

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
Freitag 28 Juni 2024 (1 Stunde vor) • GlobeNewswire Inc.

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
Freitag 21 Juni 2024 (1 Woche vor) • GlobeNewswire Inc.

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
Dienstag 11 Juni 2024 (2 Wochen vor) • GlobeNewswire Inc.

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders
Dienstag 4 Juni 2024 (3 Wochen vor) • GlobeNewswire Inc.

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials
Mittwoch 29 Mai 2024 (1 Monat vor) • GlobeNewswire Inc.

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
Freitag 17 Mai 2024 (1 Monat vor) • GlobeNewswire Inc.

Shares of Biopharma Up After News of Uplisting
Donnerstag 25 April 2024 (2 Monate vor) • AllPennyStocks.com

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
Donnerstag 25 April 2024 (2 Monate vor) • GlobeNewswire Inc.

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
Freitag 19 April 2024 (2 Monate vor) • GlobeNewswire Inc.

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
Dienstag 2 April 2024 (3 Monate vor) • GlobeNewswire Inc.

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
Mittwoch 27 März 2024 (3 Monate vor) • GlobeNewswire Inc.

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
Freitag 22 März 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere Nurexone Biologic Inc News-Artikel

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen